IMUX
NASD Immunic, Inc.$8.24 ↑ +0.68 (+8.99%) Trading Up from the previous close of $7.56, $0.36 below the day’s high of $8.60
- YTD change
- +54.39%
- vs 20-day SMA
- -12.90%
- vs 200-day SMA
- -27.67%
Price ranges
Price & Performance
+6.27 (+486.05%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 97.2% away from all-time highs of $289.90
- IMUX is up 54% since the beginning of the year
- IMUX is down 10% over the past 12 months
- IMUX is down 30% over the past 1 month
- 5% of all IMUX investors are betting against IMUX
IMUX reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is +721.7%.
- Previous minute
- -$0.03
- Last hour
- +$0.10
- Last 5 days
- -4.63%
- vs 8-day SMA
- +0.05%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
